Foreign investors are stepping up acquisitions of Japanese drug makers. Under the Foreign Exchange and Foreign Trade Act (FEFTA), such…
BUSINESS
Forxiga Replaces Januvia as Japan’s No. 1 Diabetes Drug in April-June: IQVIA
Forxiga (dapagliflozin) became the top-selling diabetes drug in Japan in April-June, according to data released by IQVIA on August 17. The SGLT2 inhibitor snapped the winning streak of the DPP-4 inhibitor Januvia (sitagliptin) for the first time in 11 years…
To read the full story
BUSINESS
- Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
- LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
- Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
- Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
- Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
MSD’s new pulmonary arterial hypertension (PAH) therapy Airwin (sotatercept) hit the Japanese market in mid-August. It’s the kind of launch…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…